Resistance mutation info of drug
| Drug General Information | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D0W9MM | ||||||||||
| Drug Name | Vinblastine | ||||||||||
| Synonyms | Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid | ||||||||||
| Drug Type | Small molecular drug | ||||||||||
| Therapeutic Class | Anticancer Agents | ||||||||||
| Company | Eli Lilly And Co | ||||||||||
| Structure |
|
||||||||||
| Drug Resistance Mutations | |||||||||||
| Target Name | Cellular tumor antigen p53 (TP53) | Target Info | |||||||||
| Gene Name | TP53 | ||||||||||
| Uniprot ID | P53_HUMAN | ||||||||||
| Species | Homo sapiens | ||||||||||
| Reference Sequence |
MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD [Homo sapiens] |
||||||||||
| Targeted Disease | Leukemia | ||||||||||
| Drug Resistance Mutations |
|
||||||||||
| References | |||||||||||
| REF 1 | A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line. Oncogene. 2000 Oct 19;19(44):5098-105. | ||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.